BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34930820)

  • 21. Cannabinoid CB
    He XH; Jordan CJ; Vemuri K; Bi GH; Zhan J; Gardner EL; Makriyannis A; Wang YL; Xi ZX
    Acta Pharmacol Sin; 2019 Mar; 40(3):365-373. PubMed ID: 29967454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats.
    Fattore L; Cossu G; Martellotta CM; Fratta W
    Psychopharmacology (Berl); 2001 Aug; 156(4):410-6. PubMed ID: 11498718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The anabolic steroid nandrolone alters cannabinoid self-administration and brain CB
    Struik D; Fadda P; Zara T; Zamberletti E; Rubino T; Parolaro D; Fratta W; Fattore L
    Pharmacol Res; 2017 Jan; 115():209-217. PubMed ID: 27890818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The GABA
    Augier E; Dulman RS; Damadzic R; Pilling A; Hamilton JP; Heilig M
    Neuropsychopharmacology; 2017 Aug; 42(9):1789-1799. PubMed ID: 28294133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse.
    Vasiljevik T; Franks LN; Ford BM; Douglas JT; Prather PL; Fantegrossi WE; Prisinzano TE
    J Med Chem; 2013 Jun; 56(11):4537-50. PubMed ID: 23631463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution.
    Nguyen T; German N; Decker AM; Langston TL; Gamage TF; Farquhar CE; Li JX; Wiley JL; Thomas BF; Zhang Y
    J Med Chem; 2017 Sep; 60(17):7410-7424. PubMed ID: 28792219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COX-2 Inhibition Antagonizes Intra-Accumbens 2-Arachidonoylglycerol-Mediated Reduction in Ethanol Self-Administration in Rats.
    Pavon FJ; Polis I; Stouffer DG; Roberto M; Martin-Fardon R; Rodriguez de Fonseca F; Parsons LH; Serrano A
    Alcohol Clin Exp Res; 2020 Nov; 44(11):2158-2165. PubMed ID: 32944989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced AMPA receptor activity increases operant alcohol self-administration and cue-induced reinstatement.
    Cannady R; Fisher KR; Durant B; Besheer J; Hodge CW
    Addict Biol; 2013 Jan; 18(1):54-65. PubMed ID: 23126443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence.
    Colombo G; Orrù A; Lai P; Cabras C; Maccioni P; Rubio M; Gessa GL; Carai MA
    Mol Neurobiol; 2007 Aug; 36(1):102-12. PubMed ID: 17952655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats.
    Rubio M; Fernández-Ruiz J; de Miguel R; Maestro B; Michael Walker J; Ramos JA
    Neuropharmacology; 2008 May; 54(6):976-88. PubMed ID: 18371990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys.
    Schindler CW; Redhi GH; Vemuri K; Makriyannis A; Le Foll B; Bergman J; Goldberg SR; Justinova Z
    Neuropsychopharmacology; 2016 Aug; 41(9):2283-93. PubMed ID: 26888056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of endocannabinoids and cannabinoid CB1 receptors in alcohol-related behaviors.
    Hungund BL; Basavarajappa BS
    Ann N Y Acad Sci; 2004 Oct; 1025():515-27. PubMed ID: 15542757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol.
    López-Moreno JA; González-Cuevas G; Navarro M
    Neurobiol Dis; 2007 Feb; 25(2):274-83. PubMed ID: 17067804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.
    Gueye AB; Pryslawsky Y; Trigo JM; Poulia N; Delis F; Antoniou K; Loureiro M; Laviolette SR; Vemuri K; Makriyannis A; Le Foll B
    Int J Neuropsychopharmacol; 2016 Dec; 19(12):. PubMed ID: 27493155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cannabinoid-1 receptor neutral antagonist reduces binge-like alcohol consumption and alcohol-induced accumbal dopaminergic signaling.
    Balla A; Dong B; Shilpa BM; Vemuri K; Makriyannis A; Pandey SC; Sershen H; Suckow RF; Vinod KY
    Neuropharmacology; 2018 Mar; 131():200-208. PubMed ID: 29109060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data.
    Maccioni P; Colombo G; Carai MA
    CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):55-9. PubMed ID: 20201816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. mGluR5 antagonism inhibits cocaine reinforcement and relapse by elevation of extracellular glutamate in the nucleus accumbens via a CB1 receptor mechanism.
    Li X; Peng XQ; Jordan CJ; Li J; Bi GH; He Y; Yang HJ; Zhang HY; Gardner EL; Xi ZX
    Sci Rep; 2018 Feb; 8(1):3686. PubMed ID: 29487381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cocaine-induced increases in motivation require 2-arachidonoylglycerol mobilization and CB1 receptor activation in the ventral tegmental area.
    Engi SA; Beebe EJ; Ayvazian VM; Cruz FC; Cheer JF; Wenzel JM; Zlebnik NE
    Neuropharmacology; 2021 Aug; 193():108625. PubMed ID: 34058192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
    Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
    Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors.
    Arnone M; Maruani J; Chaperon F; Thiébot MH; Poncelet M; Soubrié P; Le Fur G
    Psychopharmacology (Berl); 1997 Jul; 132(1):104-6. PubMed ID: 9272766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.